Skip to main content
. 2022 Jul 29;11:321–329. doi: 10.1007/s40204-022-00198-3

Table 1.

Nanoformulations’ list of curcumin that can be potentially applied for the treatment of CF

Nanoformulations Experimental model/clinical study Results References
PEG-curcumin Human bronchial epithelial cells in vitro

↑Aqueous solubility

↑Bioavailability

(Pandey et al. 2011)
DPI-curcumin RAW 264.7 cells/ in vitro High loading and sustained release of drug (El-Sherbiny and Smyth 2012)
PLGA-curcumin Mice/in vivo Effective in curing ΔF508 mutation (Cartiera et al. 2010)
Nano-curcumin (Exir Nano Sina Drug Company, Iran) Humans/clinical study

No cytotoxicity

↓ liver metabolism

↑Gastrointestinal absorption

(Talebi et al. 2021)

DPI dry powdered inhalers, PEG polyethylene glycol, PLGA poly (lactic-co-glycolic acid)